会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明授权
    • Compositions and methods for the treatment of metabolic syndrome
    • 用于治疗代谢综合征的组合物和方法
    • US09403857B2
    • 2016-08-02
    • US14399198
    • 2013-02-28
    • Mahesh Kandula
    • Mahesh Kandula
    • A61K31/675C07F9/6558C07D339/04C07D409/12
    • C07F9/65586C07D339/04C07D409/12
    • The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. such compositions may be used to treatment of fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glucose tolerance, or insulin resistance, high blood pressure, central obesity (also known as visceral, male-pattern or apple-shaped adiposity), overweight with fat deposits mainly around the waist, decreased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver (especially in concurrent obesity) progressing to NAFLD, polycystic ovarian syndrome (in women), hypophosphatemia, renal diseases, albuminuria, end stage renal disease, and acanthosis nigricans.
    • 本发明涉及式I和式II化合物或其药学上可接受的盐,以及多晶型物,溶剂合物,对映体,立体异构体和水合物。 包含有效量的式I或式II化合物的药物组合物,以及用于治疗或预防或调节代谢综合征的方法可以配制用于口服,口腔,直肠,局部,透皮,经粘膜,静脉内,肠胃外给药,糖浆或 注射。 这种组合物可用于治疗空腹高血糖症,2型糖尿病,空腹血糖受损,葡萄糖耐量降低或胰岛素抵抗,高血压,中枢性肥胖(也称为内脏,雄性模式或苹果形肥胖) 脂肪沉积主要在腰围附近,HDL胆固醇降低,甘油三酯升高,高尿酸血症,脂肪肝(特别是并发肥胖)进展到NAFLD,多囊卵巢综合征(女性),低磷血症,肾脏疾病,蛋白尿,终末期肾病, 和黑棘皮病。
    • 6. 发明授权
    • Compositions and methods for the treatment of metabolic syndrome
    • 用于治疗代谢综合征的组合物和方法
    • US09321716B1
    • 2016-04-26
    • US14533115
    • 2014-11-05
    • Mahesh Kandula
    • Mahesh Kandula
    • A61K31/21C07C69/736A61K31/235A61K47/48C07C233/49A61K31/24
    • A61K31/24A61K31/235C07C233/20
    • The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.
    • 本发明涉及式I化合物或其药学上可接受的盐,以及其多晶型物,溶剂合物,对映体,立体异构体和水合物。 包含有效量的式I化合物和用于治疗代谢综合征的方法的药物组合物可以配制用于口服,口腔,直肠,局部,透皮,经粘膜,静脉内,肠胃外给药,糖浆或注射。 此类组合物可用于治疗高尿酸血症,痛风,血脂异常,肥胖症,尿素循环障碍,高血糖症,胰岛素抵抗,糖尿病,尿崩症,1型糖尿病,2型糖尿病,微血管并发症,大血管并发症,脂质障碍,糖尿病前期, 肥胖,心律失常,心肌梗死,中风,神经病,肾并发症,高甘油三酯血症,心血管并发症和餐后高血糖症。
    • 7. 发明授权
    • Compositions and methods for the treatment of respiratory disorders
    • 用于治疗呼吸系统疾病的组合物和方法
    • US09242939B2
    • 2016-01-26
    • US14399202
    • 2013-02-24
    • Mahesh Kandula
    • Mahesh Kandula
    • C07D221/28A61K31/485C07D471/08A61K47/48
    • C07D221/28A61K31/485A61K47/48038A61K47/48061A61K47/542A61K47/545C07D471/08
    • The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of respiratory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cough caused by minor throat and bronchial irritation (such as commonly accompanies the flu and common cold), as well as those resulting from inhaled particle irritants, upper respiratory infections, (pseudobulbar affect) in patients with amyotrophic lateral sclerosis and multiple sclerosis, neuropathic pain and pain associated with fibromyalgia.
    • 本发明涉及式I化合物或其药学上可接受的盐,以及其多晶型物,溶剂合物,对映体,立体异构体和水合物。 包含有效量的式I化合物和用于治疗呼吸系统疾病的方法的药物组合物可以配制用于口服,口腔,直肠,局部,透皮,经粘膜,静脉内,肠胃外给药,糖浆或注射。 这种组合物可用于治疗由轻微喉咙和支气管刺激引起的咳嗽(例如通常伴有流感和感冒),以及由吸入性粒子刺激物引起的咳嗽症状,上呼吸道感染(假性筋感染),肌萎缩症患者 侧索硬化和多发性硬化,神经性疼痛和与纤维肌痛相关的疼痛。
    • 8. 发明申请
    • COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGIC DISEASES
    • 用于治疗神经病变的组合物和方法
    • US20150218136A1
    • 2015-08-06
    • US14399174
    • 2013-04-19
    • Mahesh KANDULA
    • Mahesh Kandula
    • C07D409/12C07D333/24
    • C07D409/12C07D333/20C07D333/24
    • The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurologic diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depression, Alzheimer's disease, multiple sclerosis, Batten disease, multiple sclerosis, Parkinson's disease (PD) and restless legs syndrome (RLS).
    • 本发明涉及式I化合物或其药学上可接受的盐,以及其多晶型物,溶剂合物,对映体,立体异构体和水合物。 包含有效量的式I化合物的药物组合物和治疗神经疾病的方法可以配制用于口服,口腔,直肠,局部,透皮,经粘膜,静脉内,肠胃外给药,糖浆或注射。 这样的组合物可用于治疗抑郁症,阿尔茨海默氏病,多发性硬化,巴特氏病,多发性硬化,帕金森病(PD)和不宁腿综合征(RLS)。
    • 10. 发明申请
    • COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION
    • 用于治疗呕吐的组合物和方法
    • US20150119453A1
    • 2015-04-30
    • US14399190
    • 2013-02-01
    • Mahesh Kandula
    • Mahesh Kandula
    • C07D339/04A61K47/48
    • C07D339/04A61K47/48038A61K47/48061A61K47/542A61K47/545C07C219/08C07C2601/14C07D209/14C07D213/20C07D213/66C07D495/04
    • The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis.
    • 本发明涉及式I化合物或其药学上可接受的盐,以及其多晶型物,溶剂合物,对映体,立体异构体和水合物。 包含有效量的式I化合物的药物组合物,以及用于治疗或预防抑郁症的方法可以配制用于口服,口腔,直肠,局部,透皮,经粘膜,静脉内,肠胃外给药,糖浆或注射。 这些组合物可用于治疗重度抑郁障碍(MDD),焦虑症,神经疾病,一般焦虑症,社交恐惧症,惊恐障碍,血管舒缩症状,糖尿病性神经病,癫痫,双相情感障碍,偏头痛,精神分裂症,癌症,绝经期,HIV 和家族性腺瘤性息肉病。